Purchase Order HT942524P0148

Award Date 9/5/24
Potential Completion Date 6/1/25
Potential Value $60K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
ABER PROV GRD, MD 21010, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $1,303,426.92 firm-fixed-price purchase order awarded by the Defense Health Agency (DHA) to Eitr Biologics, Inc., a small business biotechnology company. The contract is for sorting peripheral blood mononuclear cells from Lassa fever virus survivors to discover and produce monoclonal antibodies for assessment in in vitro and in vivo assays. The original solicitation was issued as a Request for Proposal (RFP) under NAICS code 541380, with a small business size standard of $19.0 million....
The Defense Health Agency awarded a $84,720.53 firm fixed price purchase order to Genovac Antibody Discovery LLC, a small disadvantaged business, for the generation of monoclonal antibodies targeting ferret immunoglobulin M and immunoglobulin G. This requirement was solicited as a 100% small business set-aside. The contract has an ultimate completion date of December 29, 2023 and was awarded on May 1, 2023. The contract was issued under a federal contract opportunity posted on April 7, 2023 with...
This federal contract award is a delivery order for 1,000 mcg/20 ml vials of the medication fentanyl, with a ceiling value of $1,239.00. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA), a defense agency. The contract is not set aside and is a firm fixed-price award. AmerisourceBergen Drug Corp is the prime contractor, and there is no information provided about any subcontractors. The place of performance is...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of a single medication - Fentanyl 100 mcg/2 mL vial, 2 mL. The contract has a firm fixed price of $2,109.72 and a period of performance through May 20, 2025. The award was made on May 19, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
The U.S. Defense Health Agency awarded a $34,225 firm-fixed-price delivery order contract to Leinco Technologies, Inc., a self-certified small disadvantaged business and manufacturer of goods. The contract is for the provision of monoclonal antibodies from knockout mice that have been in-vivo genetically immunized with interferon-alpha/beta receptor alpha chain protein. This contract award supports federal research initiatives related to COVID-19 and other viral pathogens. Leinco Technologies...
This delivery order is for research and development tasks associated with developing a U.S. Food and Drug Administration (FDA) licensed monoclonal antibody countermeasure for botulinum neurotoxin exposure. The $4,861,155.86 cost-plus-fixed-fee contract was awarded on June 16, 2022 to Resilience Government Services, Inc., doing business as Nanotherapeutics Inc., with a period of performance through February 28, 2025. This contract supports the Department of the Army's Joint Program Executive...
This is a firm fixed-price purchase order contract awarded by the Medical Supply Chain agency of the U.S. Department of Defense (DOD) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $2,015.25 and requires the delivery of antidote treatment products by April 25, 2024. DMS Pharmaceutical Group holds a separate indefinite delivery contract with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at...
This is a $10,532.44 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is not designated as a set-aside. The award is associated with a larger $999,999,999 Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies...
This is a $21,501.64 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of a variety of pharmaceutical products and medical supplies, including medications across therapeutic areas such as diabetes, neurology, pain management, and antibiotics, as well as specialized medical equipment. The award is not associated with a set-aside program and is part of a larger...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $30,581.85 and a performance period through April 28, 2025. The contract is not set aside and provides for the delivery of a variety of pharmaceutical and medical products, including medications across multiple therapeutic domains such as diabetes, neurology, and...

This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Celltheon Corporation, a small disadvantaged business, for the delivery of over 4 grams of anti-carfentanil monoclonal antibody (mAb) by June 1, 2025. The contract, valued at $60,000.00, supports research efforts by the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD) under an Interagency Agreement with the National Institutes of Health (NIH) and the University of Washington. The mAb is required for non-human primate studies related to carfentanil, a potent synthetic opioid. This sole-source contract was awarded without a set-aside, as Celltheon Corporation was determined to be the only source capable of providing the required mAb due to its proprietary cell line and hybridoma technology.

Generated 6/27/25, 12:14 PM